I-Mab gets new CEO after long search. Sale of the company coming next?
The drug developer filled an 18-month-long vacuum in its top position by appointing an industry veteran with a history of deal-making as its new CEO Key Takeaways: I-Mab has appointed…
I-Mab Shaken by Management Moves, Merger Talk and Delisting Threat
Cancer drug maker has been in a wide range of market-moving headlines lately, though its stock still trades near an all-time low Key Takeaways: I-Mab was placed on a list…
I-Mab Co-founds a SPAC: What’s Up With That?
Vivere Lifesciences Acquisition Corp, a special purpose acquisition company co-founded by the U.S.-listed drug maker, has filed for a Hong Kong IPO Key Takeaways: Vivere Lifesciences Acquisition Corp., whose co-founders…
As U.S. Takes Aim at China Drug Makers, Innovators Appear at Biggest Risk
Washington’s campaign to keep cutting-edge technology out of China took a new twist late last week with the addition of Chinese medical companies to U.S. blacklists Key takeaways: Washington has…
FAST NEWS: I-Mab to Move Ahead With Dual Listing in Hong Kong
The latest: U.S.-listed cancer drug developer I-Mab (IMAB.US) announced its board has approved a motion to pursue a listing on the Hong Kong Stock Exchange. The board also authorized the company's…
I-Mab Gets Boost from Latest Industry Signals on New Cancer Treatment
Company’s shares surged as much as 15% after AstraZeneca unveiled upbeat results for a new class of cancer drugs known as CD73 antibodies Key Takeaways: I-Mab’s shares surged up to…
Drug Maker I-Mab Wins Plaudits as Analysts Urge Caution on Soaring Stock
Cancer specialist’s shares have nearly doubled in the last six months after it posted its first-ever profit and named two well-connected board members Key points: I-Mab’s shares have nearly doubled…
